{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:35Z","timestamp":1761901835876,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.msard.2021.102754","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T16:08:45Z","timestamp":1610640525000},"page":"102754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients"],"prefix":"10.1016","volume":"49","author":[{"given":"Giulia","family":"Mallucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Zito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3358-8969","authenticated-orcid":false,"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Dal","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Franciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"AISM, n.d. ComunicazioneGdSSINSM-Coronavirus. URL https:\/\/www.aism.it\/sites\/default\/files\/ComunicazioneGdSSINSM-Coronavirus.pdf (accessed 11.4. 2020).","key":"10.1016\/j.msard.2021.102754_bib0001"},{"key":"10.1016\/j.msard.2021.102754_bib0002","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.25770","article-title":"SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad","volume":"87","author":"Amor","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102754_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102754_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000761","article-title":"COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102754_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102754_bib0006","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102754_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102754_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"unstructured":"ISTAT, n.d. ReportPrimiRisultatiIndagineSiero. URL https:\/\/www.istat.it\/it\/files\/\/2020\/08\/ReportPrimiRisultatiIndagineSiero.pdf (accessed 11.4 2020 ).","key":"10.1016\/j.msard.2021.102754_bib0009"},{"key":"10.1016\/j.msard.2021.102754_bib0010","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/1352458520942198","article-title":"COVID-19 in multiple sclerosis: the Dutch experience","volume":"26","author":"Loonstra","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102754_bib0011","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.102754_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102414","article-title":"Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod","volume":"45","author":"Mallucci","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102754_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008520","article-title":"Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients","volume":"16","author":"Meng","year":"2020","journal-title":"PLoS Pathog."},{"unstructured":"Multiple Sclerosis International Federation, 2020. The coronavirus and MS\u2014updated global advice. [WWW Document]. URL (accessed 6.19.20).","key":"10.1016\/j.msard.2021.102754_bib0014"},{"key":"10.1016\/j.msard.2021.102754_bib0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection\u00a0: a narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann. Intern. Med."},{"doi-asserted-by":"crossref","unstructured":"Peckham, H., de Gruijter, N.M. and Raine, C. and Radziszewska, A. and Ciurtin, C. and Wedderburn, L.R. and Rosser, E.C. and Deakin, C.T. and Webb, K., Charles, R., Radziszewska, A., Ciurtin, C., Wedderburn, L.R, Rosser, E.C, Deakin, C.T, Webb, K., 2020. Sex-Bias in COVID-19: a Meta-Analysis and Review of Sex Differences in Disease and Immunity.","key":"10.1016\/j.msard.2021.102754_bib0016","DOI":"10.21203\/rs.3.rs-23651\/v1"},{"key":"10.1016\/j.msard.2021.102754_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","volume":"396","author":"Poll\u00e1n","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102754_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.102754_bib0019","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:06Z","timestamp":1761901026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":19,"alternative-id":["S2211034821000201"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102754","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102754"}}